BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
BridgeBio Pharma’s Promising Prospects: FDA Approval of Attruby and Strategic Pricing Bolster Buy Rating
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price
BridgeBio Pharma Gets FDA Approval for Heart Disease Drug Attruby
The Palo Alto, California-based biopharmaceutical company said the Food and Drug Administration approved Attruby for adults with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular death and cardiovascular-related hospitalization.
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Attruby is the first approved product with a label that specifies near-complete TTR stabilisation. The approval triggers a $500m payment to BridgeBio under a royalty funding agreement. The ATTRibute-CM Phase III trial,
BridgeBio Pharma: FDA Endorsement and Stable Price Target Bolster Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black
FDA approves Palo Alto biotech's heart disease drug
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the opening bell Monday.
Business Insider7h
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...
Stocktwits on MSN1d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement Builds
BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
Zacks.com on MSN21h
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
ETF Daily News13h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
Seeking Alpha2d
BBIO BridgeBio Pharma, Inc.
View BridgeBio Pharma, Inc. (BBIO) current and estimated P/E ratio data provided by Seeking Alpha.
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
Investing1d
BridgeBio Pharma Inc (BBIO)
BridgeBio Pharma Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients BridgeBio Pharma, Inc. (Nasdaq: NASDAQ:BBIO) today shared positive results from the Japan ...
Why Was A.P. Bio Canceled Twice? Everything to Know About the Sitcom's History (And How Fans Brought It Back!) Before It Landed on Netflix
A.P. Bio' starring Glenn Howerton aired for two seasons on NBC and two seasons on Peacock. Here's everything to know about ...